Alpha-1 antitrypsin for cystic fibrosis complicated by severe cytokinemic COVID-19.
J Cyst Fibros
; 20(1): 31-35, 2021 01.
Article
in English
| MEDLINE | ID: covidwho-1065291
ABSTRACT
BACKGROUND:
The clinical course of severe COVID-19 in cystic fibrosis (CF) is incompletely understood. We describe the use of alpha-1 antitrypsin (AAT) as a salvage therapy in a critically unwell patient with CF (PWCF) who developed COVID-19 while awaiting lung transplantation.METHODS:
IV AAT was administered at 120 mg/kg/week for 4 consecutive weeks. Levels of interleukin (IL)-1ß, IL-6, IL-8, and soluble TNF receptor 1 (sTNFR1) were assessed at regular intervals in plasma, with IL-1ß, IL-6, IL-8 and neutrophil elastase (NE) activity measured in airway secretions. Levels were compared to baseline and historic severe exacerbation measurements.RESULTS:
Systemic and airway inflammatory markers were increased compared to both prior exacerbation and baseline levels, in particular IL-6, IL-1ß and NE activity. Following each AAT dose, rapid decreases in each inflammatory parameter were observed. These were matched by marked clinical and radiographic improvement.CONCLUSIONS:
The results support further investigation of AAT as a COVID-19 therapeutic, and re-exploration of its use in CF.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Alpha 1-Antitrypsin
/
Cystic Fibrosis
/
COVID-19
Type of study:
Case report
/
Diagnostic study
/
Prognostic study
Topics:
Long Covid
Limits:
Adult
/
Female
/
Humans
Country/Region as subject:
Europa
Language:
English
Journal:
J Cyst Fibros
Year:
2021
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS